101. Broad-Spectrum Inhibitor of Bacterial Polyphosphate Homeostasis Attenuates Virulence Factors and Helps Reveal Novel Physiology of Klebsiella pneumoniae and Acinetobacter baumannii
- Author
-
Nathan Roberge, Nolan Neville, Katya Douchant, Curtis Noordhof, Nadejda Boev, Calvin Sjaarda, Prameet M. Sheth, and Zongchao Jia
- Subjects
polyphosphate kinase (PPK) ,Acinetobacter baumannii ,Microbiology (medical) ,Klebsiella pneumoniae ,Virulence ,medicine.disease_cause ,virulence factor ,Microbiology ,Virulence factor ,03 medical and health sciences ,Polyphosphate kinase ,medicine ,Microbiome ,030304 developmental biology ,0303 health sciences ,biology ,030306 microbiology ,Pseudomonas aeruginosa ,Biofilm ,polyphosphate ,biology.organism_classification ,anti-virulence therapeutic ,QR1-502 ,3. Good health - Abstract
Acinetobacter baumannii and Klebsiella pneumoniae currently rank amongst the most antibiotic-resistant pathogens, responsible for millions of infections each year. In the wake of this crisis, anti-virulence therapeutics targeting bacterial polyphosphate (polyP) homeostasis have been lauded as an attractive alternative to traditional antibiotics. In this work, we show that the small molecule gallein, a known G-protein βγ subunit modulator, also recently proven to have dual-specificity polyphosphate kinase (PPK) inhibition in Pseudomonas aeruginosa, in turn exhibits broad-spectrum PPK inhibition in other priority pathogens. Gallein treatment successfully attenuated virulence factors of K. pneumoniae and A. baumannii including biofilm formation, surface associated motility, and offered protection against A. baumannii challenge in a Caenorhabditis elegans model of infection. This was highlighted most importantly in the critically understudied A. baumannii, where gallein treatment phenocopied a ppk1 knockout strain of a previously uncharacterized PPK1. Subsequent analysis revealed a unique instance of two functionally and phenotypically distinct PPK1 isoforms encoded by a single bacterium. Finally, gallein was administered to a defined microbial community comprising over 30 commensal species of the human gut microbiome, demonstrating the non-disruptive properties characteristic of anti-virulence treatments as microbial biodiversity was not adversely influenced. Together, these results emphasize that gallein is a promising avenue for the development of broad-spectrum anti-virulence therapeutics.
- Published
- 2021
- Full Text
- View/download PDF